암 백신 시장 규모, 점유율, 성장 및 세계 업계 분석, 지역별 동향 및 예측(2026-2034년)

Growth Factors of cancer vaccines Market

The global cancer vaccines market was valued at USD 11.62 billion in 2025 and is expected to grow from USD 12.71 billion in 2026 to USD 45.37 billion by 2034, registering a CAGR of 17.25% during the forecast period. North America dominated the global market with a 38.3% market share in 2025, supported by advanced healthcare infrastructure, increasing cancer research, and rapid adoption of personalized immunotherapy.

Cancer vaccines include both preventive vaccines, which reduce the risk of virus-associated cancers such as cervical cancer, and therapeutic vaccines, which stimulate the immune system to recognize and destroy cancer cells. The growing global burden of cancer, combined with technological advancements in mRNA platforms, neoantigen discovery, tumor sequencing, and precision medicine, is accelerating market expansion. Pharmaceutical companies are investing heavily in research and development to introduce innovative vaccines that improve treatment outcomes while reducing recurrence rates.

Cancer Vaccines Market Trends

One of the major trends transforming the market is the growing use of artificial intelligence (AI) and bioinformatics for identifying tumor-specific antigens. AI-powered platforms enable researchers to analyze genomic and immune-response data faster, helping develop personalized cancer vaccines with improved effectiveness. In addition, the success of mRNA vaccine technology has encouraged manufacturers to expand research into individualized cancer vaccines that target unique mutations in each patient's tumor. Increasing collaboration between biotechnology firms and pharmaceutical companies is further driving innovation across preventive and therapeutic vaccine development.

Market Drivers

The primary factor driving the cancer vaccines market growth is the increasing adoption of therapeutic vaccines alongside immune checkpoint inhibitors. Combination immunotherapy improves the immune system's ability to recognize and eliminate cancer cells while reducing the chances of disease recurrence. Rising global cancer incidence, expanding immunization programs for HPV and Hepatitis B vaccines, favorable government initiatives, and continuous advancements in personalized oncology are creating strong demand for cancer vaccines across developed and emerging healthcare markets.

Market Restraints

Despite promising developments, several factors continue to limit market growth. Therapeutic cancer vaccines often face challenges in demonstrating consistent clinical effectiveness across different cancer types. Long development timelines, expensive clinical trials, complex regulatory approvals, and high manufacturing costs further restrict commercialization. Personalized vaccines also require tumor sequencing and customized production, making treatment more expensive and limiting accessibility in lower-income regions.

Market Opportunities

Growing investment in personalized neoantigen vaccines presents one of the strongest opportunities for future market expansion. Improvements in genomic sequencing, AI-driven antigen prediction, and mRNA technology are enabling companies to develop highly targeted vaccines for individual patients. Increasing collaborations between pharmaceutical companies, biotechnology firms, and research institutions are expected to accelerate commercialization. Expanding vaccination programs in emerging countries and greater awareness regarding cancer prevention will also create long-term growth opportunities.

Market Segmentation

Based on type, the market is segmented into preventive and therapeutic vaccines. The preventive segment dominated the market in 2025 due to the widespread use of HPV and Hepatitis B vaccines through national immunization programs. Meanwhile, the therapeutic segment is projected to witness the fastest growth as personalized immunotherapy gains wider clinical acceptance.

By technology, the market includes molecular-based, vector-based, and cell-based vaccines. Molecular-based vaccines accounted for the largest share because of rapid advancements in DNA, RNA, peptide, and protein-based vaccine technologies.

Based on indication, cervical cancer remained the leading segment owing to the global success of HPV vaccination programs. Lung cancer is expected to experience the fastest growth due to expanding clinical research in personalized immunotherapy.

By distribution channel, hospitals dominated the market because of increasing patient visits, advanced oncology care facilities, and higher availability of cancer vaccines.

Regional Outlook

North America led the global cancer vaccines market in 2025 with a valuation of USD 4.45 billion. Strong research infrastructure, rapid adoption of personalized medicine, high healthcare spending, and active clinical trials continue to support regional leadership. The U.S. remains the largest contributor due to increasing investment in immuno-oncology and mRNA-based cancer vaccine development.

Europe represents the second-largest market, supported by government-backed vaccination initiatives, growing oncology research, and expanding public health programs aimed at cancer prevention. Countries such as Germany and the U.K. continue investing in advanced vaccine research and personalized therapies.

Asia Pacific is expected to witness substantial growth throughout the forecast period due to increasing cancer incidence, expanding healthcare infrastructure, rising awareness regarding preventive vaccination, and government support for biotechnology innovation. China, Japan, and India are investing heavily in vaccine manufacturing and cancer research.

Latin America and the Middle East & Africa are also experiencing gradual market expansion as governments strengthen immunization programs, improve healthcare access, and increase investments in cancer screening and prevention initiatives.

Competitive Landscape

The cancer vaccines market is highly competitive, with leading companies focusing on research collaborations, product innovation, clinical trials, and strategic partnerships. Major players include Dendreon Pharmaceuticals LLC., Serum Institute of India Pvt. Ltd., Merck & Co., Inc., GSK plc, Moderna, Inc., BioNTech SE, Walvax Biotechnology Co., Ltd., Synthaverse S.A., Center of Molecular Immunology, and Wantai BioPharm. These companies continue investing in mRNA technology, personalized vaccine development, and next-generation immunotherapy platforms to strengthen their global market position.

Recent industry developments highlight the market's innovation pace. In 2026, Anixa Biosciences partnered with Cytovance Biologics to manufacture clinical materials for its breast cancer vaccine. During 2025, several companies expanded HPV vaccine accessibility, introduced new personalized vaccine candidates, and strengthened collaborations aimed at accelerating cancer prevention and treatment.

Conclusion

The global cancer vaccines market is entering a period of rapid expansion as healthcare systems increasingly prioritize cancer prevention, precision medicine, and personalized immunotherapy. Valued at USD 11.62 billion in 2025, the market is projected to reach USD 12.71 billion in 2026 and USD 45.37 billion by 2034, driven by continuous technological advancements, expanding immunization programs, increasing research investments, and growing adoption of innovative therapeutic cancer vaccines worldwide.

Segmentation By Type, Technology, Indication, Distribution Channel, and Region

By Type * Preventive

• Therapeutic

By Technology * Molecular-based

• Vector-based
• Cell-based

By Indication * Cervical Cancer

• Bladder Cancer
• Prostate Cancer
• Lung Cancer
• Others

By Distribution Channel * Hospitals

• Government & Organization Supply
• Others

By Region *

• North America (By Type, By Technology, By Indication, By Distribution Channel, By Country)
  • U.S.
  • Canada
• Europe (By Type, By Technology, By Indication, By Distribution Channel, By Country/Sub-Region)
  • France
  • Italy
  • Spain
  • U.K.
  • Germany
  • Rest of Europe
• Asia Pacific (By Type, By Technology, By Indication, By Distribution Channel, By Country/Sub-Region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Type, By Technology, By Indication, By Distribution Channel, By Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, By Technology, By Indication, By Distribution Channel, By Country/Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Challenges
• 3.5. Market Trends

4. Key Insights

• 4.1. Prevalence of Different Cancers, by Key Countries, 2025
• 4.2. Overview of Regulatory Scenario by Key Countries/Regions
• 4.3. Pipeline Analysis, Key Players
• 4.4. Key Industry Developments - Mergers, Acquisitions & Partnerships
• 4.5. New Product Launches
• 4.6. Product & Revenue Mapping: Global Cancer Vaccines Market

5. Global Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Preventive
  • 5.1.2. Therapeutic
• 5.2. Market Analysis, Insights and Forecast - By Technology
  • 5.2.1. Molecular-based
  • 5.2.2. Vector-based
  • 5.2.3. Cell-based
• 5.3. Market Analysis, Insights and Forecast - By Indication
  • 5.3.1. Cervical Cancer
  • 5.3.2. Bladder Cancer
  • 5.3.3. Prostate Cancer
  • 5.3.4. Lung Cancer
  • 5.3.5. Others
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospitals
  • 5.4.2. Government & Organization Supply
  • 5.4.3. Others
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Preventive
  • 6.1.2. Therapeutic
• 6.2. Market Analysis, Insights and Forecast - By Technology
  • 6.2.1. Molecular-based
  • 6.2.2. Vector-based
  • 6.2.3. Cell-based
• 6.3. Market Analysis, Insights and Forecast - By Indication
  • 6.3.1. Cervical Cancer
  • 6.3.2. Bladder Cancer
  • 6.3.3. Prostate Cancer
  • 6.3.4. Lung Cancer
  • 6.3.5. Others
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospitals
  • 6.4.2. Government & Organization Supply
  • 6.4.3. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Preventive
  • 7.1.2. Therapeutic
• 7.2. Market Analysis, Insights and Forecast - By Technology
  • 7.2.1. Molecular-based
  • 7.2.2. Vector-based
  • 7.2.3. Cell-based
• 7.3. Market Analysis, Insights and Forecast - By Indication
  • 7.3.1. Cervical Cancer
  • 7.3.2. Bladder Cancer
  • 7.3.3. Prostate Cancer
  • 7.3.4. Lung Cancer
  • 7.3.5. Others
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospitals
  • 7.4.2. Government & Organization Supply
  • 7.4.3. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.5.1. France
  • 7.5.2. Italy
  • 7.5.3. Spain
  • 7.5.4. U.K.
  • 7.5.5. Germany
  • 7.5.6. Rest of Europe

8. Asia Pacific Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Preventive
  • 8.1.2. Therapeutic
• 8.2. Market Analysis, Insights and Forecast - By Technology
  • 8.2.1. Molecular-based
  • 8.2.2. Vector-based
  • 8.2.3. Cell-based
• 8.3. Market Analysis, Insights and Forecast - By Indication
  • 8.3.1. Cervical Cancer
  • 8.3.2. Bladder Cancer
  • 8.3.3. Prostate Cancer
  • 8.3.4. Lung Cancer
  • 8.3.5. Others
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospitals
  • 8.4.2. Government & Organization Supply
  • 8.4.3. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Preventive
  • 9.1.2. Therapeutic
• 9.2. Market Analysis, Insights and Forecast - By Technology
  • 9.2.1. Molecular-based
  • 9.2.2. Vector-based
  • 9.2.3. Cell-based
• 9.3. Market Analysis, Insights and Forecast - By Indication
  • 9.3.1. Cervical Cancer
  • 9.3.2. Bladder Cancer
  • 9.3.3. Prostate Cancer
  • 9.3.4. Lung Cancer
  • 9.3.5. Others
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospitals
  • 9.4.2. Government & Organization Supply
  • 9.4.3. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Preventive
  • 10.1.2. Therapeutic
• 10.2. Market Analysis, Insights and Forecast - By Technology
  • 10.2.1. Molecular-based
  • 10.2.2. Vector-based
  • 10.2.3. Cell-based
• 10.3. Market Analysis, Insights and Forecast - By Indication
  • 10.3.1. Cervical Cancer
  • 10.3.2. Bladder Cancer
  • 10.3.3. Prostate Cancer
  • 10.3.4. Lung Cancer
  • 10.3.5. Others
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospitals
  • 10.4.2. Government & Organization Supply
  • 10.4.3. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Dendreon Pharmaceuticals LLC.
  • 11.2.2. Serum Institute of India Pvt. Ltd.
  • 11.2.3. Merck & Co., Inc.
  • 11.2.4. GSK plc
  • 11.2.5. Walvax Biotechnology Co., Ltd.
  • 11.2.6. Synthaverse S.A.
  • 11.2.7. Center of Molecular Immunology
  • 11.2.8. Moderna, Inc.
  • 11.2.9. Wantai BioPharm
  • 11.2.10. BioNTech SE